Cholangiocarcinoma, Primary Sclerosing Cholangitis, PSC
Conditions
Brief summary
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Detailed description
The study will ask participants to provide bile and/or bile duct cytology brushings at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal). The bile and brushings will be used to generate and perpetuate bile-derived organoids using an established matrigel-based protocol. These organoids will then be used in downstream experiments to better understand disease-specific alterations to biological pathways informative of disease pathogenesis
Interventions
None listed
Sponsors
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
PSC * Patients diagnosed with PSC between the age of 18 and 85. * The diagnosis of PSC will be based on standard PSC criteria including clinical and biochemical evidence of chronic cholestasis of at least six months duration, positive cholangiographic findings and compatible liver biopsies if available. * Women with PSC of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation. Patients with PSC and Cholangiocarcinoma will be included. Controls • Controls without history of PSC or evidence of other chronic liver disease of either gender that will participate in this study should be between the ages of 18-85.
Exclusion criteria
* Patients unable to provide inform consent. * Prisoners and institutionalized individuals. * PSC with orthotopic liver transplantation * History of Roux En Y procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants in study. | 20 years | Number of participants in study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of samples (per type) | 20 years | Number of samples collected (bile liquid, biliary cells) |
| Number of clinical phenotypes and/or observations. | 20 years | Number of clinical phenotypes and/or endpoints observed (i.e. disease progression, liver ca development, organoids.) |
Countries
United States
Contacts
CONTACTErik Schlicht, CCRP
CONTACTJackie Bianchi
PRINCIPAL_INVESTIGATORKonstantinos Lazaridis, MD
Mayo Clinic
Outcome results
None listed